Improving the quality of cancer clinical trials workshop summary
Scientists and clinicians seek a new paradigm that could improve the efficiency, cost-effectiveness, and overall success rate of cancer clinical trials, while maintaining the highest standards of quality. To explore innovative paradigms for cancer clinical trials and other ways to improve their qual...
| Autores Corporativos: | , |
|---|---|
| Otros Autores: | , |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Washington, D.C. :
National Academies Press
©2008.
|
| Colección: | National Academies ebooks.
|
| Acceso en línea: | Conectar con la versión electrónica |
| Ver en Universidad de Navarra: | https://innopac.unav.es/record=b44922656*spi |
Tabla de Contenidos:
- Introduction
- New clinical trial designs. Phase 0 trials
- Adaptive trial designs
- Targeting multiple pathways with multiple drugs
- Preclinical model systems
- Molecular imaging. Current and developing methods
- Challenges of molecular imaging
- Screening for predictive markers. The challenges of clinical validation
- Bioimaging predictive markers
- Clinical translation
- Panel discussion
- Costs of clinical trials. Regulatory costs
- Patient accrual
- Global outsourcing
- Time is money
- Public-private collaborations
- Regulatory issues. Regulatory barriers to innovation
- Patient advocacy perspective
- Regulation of in vitro diagnostics
- Regulatory issues in improving cancer clinical trials
- Reports from the case study discussion groups. Adaptive trial design
- Phase 0 trials
- Imaging
- Use of proteomics/genomics to assign therapy in lung cancer
- Use of genetics/genomics to assign therapy.
